Our pipeline at a glance

Updated July 31, 2020. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Download Merck Pipeline PDF

Phase 2 12 Programs
  • Anti-Viral SARS-CoV-2 infection MK-44821
  • Chikungunya virus Vaccine V184
  • HIV-1 infection islatravir (MK-8591)
  • Schizophrenia MK-8189
  • Non-small cell lung cancer MK-76842
  • Melanoma MK-76842
  • Overgrowth syndrome MK-7075
  • Non-small cell lung cancer MK-58902
  • Non-small cell lung cancer MK-42802
  • Hematological malignancies MK-42802
  • Melanoma cancer V937
  • Head and neck cancer MK-14542
  • Non-small cell lung cancer MK-13082
  • Melanoma MK-13082
  • Hematological malignancies MK-1026
  • Advanced solid tumors LYNPARZA® (MK-7339) 1, 3
  • Advanced solid tumors LENVIMA® (MK-7902) 1, 2
  • Advanced solid tumors KEYTRUDA® (MK-3475)
  • Respiratory syncytial virus MK-1654
  • Cytomégalovirus vaccine V160
Phase 3 24 Programs
  • HIV-1 infection MK-8591A (doravirine/islatravir)
  • Ovarian cancer KEYTRUDA® (MK-3475)
  • Non-small cell lung cancer LYNPARZA® (MK-7339) 1, 2
  • Head & neck squamous cell carcinoma LENVIMA® (MK-7902) 1, 2
  • Non-small cell lung cancer LENVIMA® (MK-7902) 1, 2
  • Melanoma cancer LENVIMA® (MK-7902) 1, 2
  • Liver LENVIMA® (MK-7902) 1, 2
  • Endometrial cancer LENVIMA® (MK-7902)1, 2 (EU)
  • Bladder cancer LENVIMA® (MK – 7902) 1, 2
  • Prostate cancer KEYTRUDA® (MK-3475)
  • Esophageal Cancer KEYTRUDA® (MK-3475) (EU)
  • Nasopharyngeal cancer KEYTRUDA® (MK-3475)
  • Mesothelioma cancer KEYTRUDA® (MK-3475)
  • Biliary tract cancer KEYTRUDA® (MK-3475)
  • Small cell lung cancer KEYTRUDA® (MK-3475) (EU)
  • Liver cancer KEYTRUDA® (MK-3475) (EU)
  • Gastric cancer KEYTRUDA® (MK-3475) (EU)
  • Endometrial cancer KEYTRUDA® (MK-3475) (EU)
  • Cutaneous squamous cell carcinoma KEYTRUDA®
    (MK-3475) (EU)
  • Cervical cancer KEYTRUDA® (MK-3475) (EU)
  • Breast cancer KEYTRUDA® (MK-3475) (EU)
  • Cancer RCC MK-6482
  • Cough gefapixant (MK-7264)
  • Pneumoconjugate vaccine V114
Under review 3 Programs
  • Heart failure vericiguat (MK-1242)2 ( US,EU, JPN)
  • Bacterial infection-RECARBRIO™
    relebactam+imipenem/cilastatin
    MK-7655A (JPN)
  • Pediatric neurofibromatosis type-1 KOSELUGO® (MK-5618)1 (EU)

Therapeutic Key Areas

  • 1 - Being developed in collaboration.
  • 2 - Being developed in combination with KEYTRUDA.
  • 3 - Being developed as a monotherapy and in combination with KEYTRUDA.

What do the phases of clinical trials mean?

Phase 1

Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always.  The trial often takes place in a hospital. The goals are to determine:

  • If the medicine or vaccine is safe
  • If there are any side effects
  • How the medicine is broken down by and discharged from the body
  • How much medicine is needed and how often
  • For a vaccine, researchers see if it causes the desired response from the body’s immune system

Phase 1 trials an take from six months to one year to complete.


Phase 2

Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:

  • How well the medicine or vaccine works
  • If the medicine or vaccine is safe
  • If there are any side effects
  • How much of the medicine or vaccine is needed and how often

Phase 2 trials can take from six months to one year or more to complete.


Phase 3

Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:

  • Confirm that the medication or vaccine is effective
  • Identify and monitor side effects
  • Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.

Under review

The application has been submitted to the regulatory authorities for review.


No Duty to Update

The information contained in this chart was current as of July 31, 2020. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after July 31, 2020.

The chart reflects the company research pipeline as of July 31, 2020.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.